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Immunological self-tolerance is critical for the 
prevention of autoimmunity and maintenance   
of immune homeostasis. CD4+CD25+ regula-
tory T cells (T reg cells) play a major role in   
this process and represent a T cell subset of   
thymic origin that is dependent on the expres-
sion of the forkhead family transcription factor 
Foxp3 (Fontenot et al., 2003; Hori et al., 2003).   
T reg cells have been shown to down-regulate 
many  types  of  immune  responses,  including 
potentially harmful effector immune reactions 
(Sakaguchi, 2005). However, the pathways that 
lead to the induction of Foxp3 expression and 
control T reg cell development and homeosta-
sis remain largely unknown. Foxp3 deficiency 
leads to the scurfy phenotype in mice and to the 
life-threatening  IPEX  (immunodysregulation 
polyendocrinopathy  enteropathy  X-linked) 
syndrome in humans, a disease characterized by 
extensive  lymphoproliferation  and  multiple   
autoimmune disorders (Ochs et al., 2005).   
In contrast, Foxp3 overexpression in transgenic 
mice  causes  lymphopenia  and  immunodefi-
ciency (Khattri et al., 2001). Efficient control 
of the T reg cell population size and function 
is thus necessary to ensure a balance between 
self-tolerance and immune responsiveness.
Extracellular nucleotides may play a cen-
tral role in this process. Notably, ATP and 
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CD4+CD25+FoxP3+ regulatory T cells (T reg cells) play a major role in the control of  
immune responses but the factors controlling their homeostasis and function remain poorly 
characterized. Nicotinamide adenine dinucleotide (NAD+) released during cell damage or 
inflammation results in ART2.2–mediated ADP-ribosylation of the cytolytic P2X7 receptor 
on T cells. We show that T reg cells express the ART2.2 enzyme and high levels of P2X7 and 
that T reg cells can be depleted by intravenous injection of NAD+. Moreover, lower T reg cell 
numbers are found in mice deficient for the NAD-hydrolase CD38 than in wild-type,  
P2X7-deficient, or ART2-deficient mice, indicating a role for extracellular NAD+ in T reg 
cell homeostasis. Even routine cell preparation leads to release of NAD+ in sufficient  
quantities to profoundly affect T reg cell viability, phenotype, and function. We demonstrate 
that T reg cells can be protected from the deleterious effects of NAD+ by an inhibitory  
ART2.2-specific single domain antibody. Furthermore, selective depletion of T reg cells by 
systemic administration of NAD+ can be used to promote an antitumor response in several 
mouse tumor models. Collectively, our data demonstrate that NAD+ influences survival, 
phenotype, and function of T reg cells and provide proof of principle that acting on the 
ART2–P2X7 pathway represents a new strategy to manipulate T reg cells in vivo.
© 2010 Hubert et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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nicotinamide adenine dinucleotide (NAD+) released by cell 
lysis or nonlytic mechanisms (Bruzzone et al., 2001; Contreras 
et al., 2002) can activate the P2X7 receptor and induce T cell 
death (Seman et al., 2003; Scheuplein et al., 2009). P2X7 is an 
ATP-gated ion channel expressed on many cells of the im-
mune system (Di Virgilio et al., 2001). On T cells, we previ-
ously  showed  that  P2X7  activation  induces  rapid  shedding   
of CD62L, externalization of phosphatidylserine (PS) on the   
cell surface, and, ultimately, cell death (Seman et al., 2003; 
Scheuplein et al., 2009). On macrophages, it also causes mem-
brane blebbing and caspase-dependent release of proinflam-
matory cytokines such as IL-1 and IL-18 (Di Virgilio, 2007). 
Remarkably, however, although relatively high ATP concen-
trations (0.2–1 mM) are required for P2X7 activation, we have 
shown that micromolar concentrations of NAD+ are sufficient 
to  activate  P2X7  on  mouse  T  lymphocytes  (Seman  et  al., 
2003). This results from ADP ribosylation of P2X7 on arginine 
125  mediated  by  the  mono–ADP-ribosyltransferase  (ART) 
ART2.2 (Adriouch et al., 2008), which catalyzes the covalent 
transfer of the ADP-ribose group from NAD+ onto arginine 
residues of membrane target proteins (Seman et al., 2003). 
Consequently, NAD+ released during inflammation partici-
pates in the regulation of T cell homeostasis in vivo through an 
ART2.2-dependent  P2X7-mediated  mechanism  (Adriouch   
et al., 2007), a process which is now referred to as NAD- 
induced cell death (NICD; Seman et al., 2003). NICD is con-
trolled in part by the NAD-glycohydrolase CD38, which limits 
substrate availability for ART2.2 by hydrolyzing extracellular 
NAD+ (Krebs et al., 2005).
It has recently been shown that mouse Foxp3+ T reg cells 
are susceptible to cell death induced by exogenous nucleotides 
(Aswad et al., 2005), but little is known about the role of 
NICD in vivo and its consequences on T reg cell homeostasis. 
Hence, we investigated how NAD+ could regulate the T reg 
cell compartment by analyzing T reg cell number, phenotype, 
and function in mice deficient for P2X7, ART2, or CD38. 
We demonstrate that endogenous NAD+ indeed controls the 
pool of Foxp3+ T cells by an ART2/P2X7-dependent pro-
cess and that NAD+ released during preparation of primary 
Figure 1.  T reg cells are sensitive to NICD in vivo. CD38/ and WT 
mice were injected i.v. with either 10 or 60 mg NAD+, respectively, or with 
PBS and analyzed 24 h later. (A) LN, spleen, and blood cells were stained 
for CD4, CD25, and Foxp3 and analyzed by flow cytometry. Representative 
CD25/Foxp3 immunophenotyping data of the CD4+-gated population are 
shown. Numbers indicate percentage of cells in each quadrant. (B) Histo-
grams represent absolute mean numbers (pool of six LNs) of CD4+Foxp3+ 
or CD4+Foxp3 cells from CD38/ or WT mice that had been injected 
with NAD+. (C) Flow cytometry analyses of the expression of CD44, CD62L, 
and CD103 on the surface of CD4+Foxp3+ gated T reg cells 24 h after sys-
temic administration of NAD+. Numbers indicate percentage of cells in 
each quadrant. (D) Flow cytometry analyses of the expression of ART2.2 
and P2X7 on the surface of CD4+Foxp3+ gated T reg cells 24 h after sys-
temic administration of NAD+ (shaded histogram) or PBS (open histo-
gram). Negative staining controls are depicted by a dashed line.  
(E) Histograms represent absolute mean numbers of CD4+Foxp3+ T cells 
enumerated from six pooled LNs harvested from the indicated mice. Data 
are representative of at least three independent experiments, each one 
performed with a minimum of five mice per group. Error bars represent 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Remarkably, T reg cells showed a higher level of expres-
sion of P2X7 than T conv cells (Fig. 2 A). Also, T reg cells 
displayed ART activity when assayed in vitro (not depicted) 
and, accordingly, display ART2.2 expression on their sur-
face (Fig. 2 A). Hence, differences in P2X7 expression levels 
in T conv cells and T reg cells correlate with their differential 
sensitivity to NICD in vivo (Fig. 1, A and B).
To determine whether the higher sensitivity of T reg cells 
compared with T conv cells to NAD+ in vivo is linked to cell-
intrinsic differences (e.g., expression level of P2X7) rather 
lymphocytes  profoundly  affects  T  reg  cell  phenotype  and 
function. Moreover, we provide proof of principle that it is 
possible to manipulate T reg cells in vivo via the ART2–P2X7 
pathway: an ART2.2-blocking single domain antibody (sdAb) 
can be used to protect T reg cells from NAD+-induced cell 
death, whereas, conversely, NAD+ can be used to dampen   
T reg cell function and promote antitumor responses.
RESULTS AND DISCUSSION
Susceptibility of T reg cells to extracellular NAD+ in vivo
To evaluate the effect of NAD+ on T reg cells in vivo, we ana-
lyzed the compartment of CD4+CD25+Foxp3+ T cells after 
i.v. injection of NAD+. For this, we used WT and CD38/ 
mice that lack the major enzyme responsible for extracellular 
NAD+ degradation and in which the bioavailability of NAD+ 
is augmented (Partida-Sánchez et al., 2001; Krebs et al., 2005). 
When analyzed in terms of relative cell frequency and absolute 
cell number, NAD treatment led to a 75–80% reduction of   
T reg cell frequency in both WT and CD38/ mice, although 
a sixfold higher dose of NAD+ was required to induce compa-
rable effects in WT mice (Fig. 1, A and B). Analysis of the ef-
fect of NAD+ on CD4+Foxp3 conventional T cells (T conv 
cells)  revealed  that  they  were  dramatically  less  sensitive  to 
NAD+ than their T reg cell counterparts (Fig. 1 B). 1 d after 
NAD treatment, surviving T reg cells were enriched in cells 
with a classical activated/memory phenotype, i.e., CD44hi 
CD62LloCD103+ (Fig. 1 C), and were also P2X7lo and 
ART2.2lo (Fig. 1 D), suggesting that activated/memory T reg 
cells are less sensitive to NICD than naive T reg cells.
The observation that exogenous NAD+ can modulate the 
size and the phenotype of the T reg cell pool in vivo sug-
gested that endogenous NAD+ could participate in T reg cell 
homeostasis. To explore this hypothesis, we measured the 
size of the T reg cell population in LNs from unmanipulated 
CD38/, ART2/, and P2X7/ mice (Fig. 1 E). The re-
duced capacity of CD38/ animals to degrade extracellular 
NAD+ was associated with significantly lower numbers of   
T reg cells than in WT mice (Fig. 1 E). In contrast, mice that 
are  insensitive  to  NICD  because  of  genetic  deletion  of 
ART2.2 or P2X7 had higher numbers of T reg cells, which 
is consistent with the notion that endogenous NAD+ shapes 
the T reg cell compartment in vivo.
High expression of P2X7 by T reg cells correlates  
with a high sensitivity of T reg cells to NICD
To explore the mechanism accounting for the differential sus-
ceptibility of T reg cells and T conv cells to NICD, we further 
investigated their phenotype in terms of ART2.2 and P2X7 
expression and sensitivity to cell death induced by NAD+  
ex vivo. Antibody-based staining for intracellular Foxp3 requires 
cell permeabilization, precluding a distinction between live 
and apoptotic or dead cells. DEREG mice, which express a 
DTR-eGFP fusion protein under the control of the foxp3 
promoter, allow more direct analysis of T reg cells (Lahl et al., 
2007). We transferred the transgene from DEREG mice to 
CD38/, ART2/, and P2X7/ animals by backcrossing. 
Figure 2.  T reg cells express higher levels of cell surface P2X7 and 
are more sensitive to NICD in vitro than CD4+ T conv cells. (A) Flow 
cytometry analyses of ART2.2 and P2X7 cell surface expression on CD4+ 
gated LN cells from DEREG/WT mice (open histograms) or respective 
DEREG/ART2/ or DEREG/P2X7/ mice (shaded histograms). (B) LN cells 
from DEREG/WT, DEREG/ART2/, or DEREG/P2X7/ mice were incubated 
with 30 µM NAD+ for 20 min at 37°C before staining with annexin V and 
flow cytometry analyses. Numbers indicate percentage of cells in each 
quadrant. (C–E) Splenocytes from DEREG/WT or DEREG/ART2/ mice 
were incubated at 37°C with 30 µM NAD+ for the indicated times (C and D) 
or with the indicated concentrations of NAD+ for 15 min (E). Cells were 
stained with -CD4 and with annexin V and PI before flow cytometry 
analyses. T conv cells correspond to CD4+GFP gated population and T reg 
cells to the CD4+GFP+ gated population. Data are representative of three 
independent experiments.2564 NAD+ affects T reg cell survival and function | Hubert et al.
P2X7/ mice (Fig. 2, B and C). The results of kinetic and 
dose-response analyses underscore the much higher sensitivity 
of T reg cells than T conv cells to NICD (Fig. 2, D and E).
NAD+ released during preparation of T reg cells causes 
shedding of CD62L and externalization of PS
Because T reg cells are highly sensitive to NICD, we hypothe-
sized that they might already be profoundly affected by NAD+ 
released during routine ex vivo isolation. Indeed, we have re-
cently shown that NAD+ released during preparation of pri-
mary spleen and LN cells induces ADP ribosylation of P2X7 
even at 4°C. When cells are subsequently returned to 37°C, 
for example, for functional analysis, this results in the activation 
of P2X7 on a fraction of T cells (Scheuplein et al., 2009). We 
thus examined whether T reg cells shed CD62L and/or exter-
nalize PS on the cell surface as early signs of ART2–P2X7 
pathway triggering in vitro. To this end, spleen cells were care-
fully prepared on ice and were either maintained at 4°C or in-
cubated for 15 min at 37°C. They were subsequently stained 
with anti-CD62L (Fig. 3 A) or annexin V (Fig. 3 B) for evalu-
ation of P2X7 activation. The results show that most T reg 
cells from CD38/ mice spontaneously shed CD62L when 
incubated at 37°C, as the proportion of CD62L+ cells among 
the GFP+ T reg cell population dropped from 70 to <20% 
(Fig. 3 A). A similar effect was observed in cells from WT 
mice, as >75% T reg cells express CD62L+ when cells were 
kept at 4°C, whereas only <30% do so upon incubation at 
37°C (Fig. 3 A). Importantly, this phenomenon was ART2 
and P2X7 dependent because it was not observed in cells from 
ART2/ or P2X7/ mice. Similarly, annexin V staining 
showed that most T reg cells from both CD38/ and WT 
mice undergo spontaneous apoptosis when incubated at 
37°C, whereas T reg cells from ART2/ or P2X7/ mice 
than to any other in vivo confounding factor, we conducted   
a more detailed comparison of the effects of NAD+ on these 
populations in vitro (Fig. 2, B–E). Incubation of cells with 
micromolar concentrations of NAD+ induced externalization 
of PS (Fig. 2, B and C), followed by irreversible uptake of 
propidium iodide (PI; Fig. 2 C), on the vast majority of T reg 
cells. NICD of T reg cells was ART2 and P2X7 dependent 
because it was not observed in cells from ART2/ or 
Figure 3.  NAD+ released during cell preparation induces ART2.2/
P2X7-dependent CD62L shedding and PS exposure on T reg cells, 
which can be prevented by systemic injection of the ART2.2-inhibiting 
sdAb s+16a. Spleen cells from DEREG/WT, DEREG/ART2/, DEREG/
P2X7/, and DEREG/CD38/ mice were collected and kept on ice. Cell 
suspensions were incubated for 15 min at 4 or 37°C and subsequently 
stained for CD4, PI, and CD62L (A) or annexin V (B). (C) Splenocytes were 
obtained from DEREG/WT or DEREG/CD38/ mice 10 min after systemic 
injection of PBS or 300 µg of sdAb s+16a. Cells were then incubated for 
15 min at 37°C before staining with anti-CD4, PI, and annexin V (top), 
CD62L (middle), or CD27 (bottom). All FACS data are gated on live (PI) 
CD4+ cells. Numbers indicate the percentage of cells in each quadrant. 
Results are representative of three independent experiments.
Figure 4.  Inhibition of T reg cell suppressive functions in vitro by 
NAD+. (A) CD4+CD25+ T reg cells were isolated from WT or ART2/ mice 
and cultured at a 1:1 ratio with CD4+CD25 T conv cells from an ART2/ 
mouse. Cells were stimulated with Con A in the absence or presence of 
increasing concentrations of exogenously added NAD+. Proliferation was 
assayed by incorporation of [3H]-TdR on day 3. (B) CD4+CD25+ T reg cells 
were isolated from WT and ART2/ mice and cultured with CD4+CD25  
T conv cells from a WT mouse at the indicated ratios. Stimulation of  
culture and cell proliferation were performed as in A. Data are representa-
tive of four independent experiments, each one performed in triplicate. 
Error bars represent SEM.JEM VOL. 207, November 22, 2010  2565
Brief Definitive Report
are resistant (Fig. 3 B). It is of note that incubation of cells at 
37°C resulted in a gradual disappearance of T reg cells from the 
live cell gate used for FACS analyses, a phenomenon which 
was enhanced upon addition of exogenous NAD+ or ATP 
(unpublished data). Collectively, these results show that inad-
vertent NAD+ release during preparation of lymphocytes is 
sufficient to induce NICD on a large fraction of T reg cells. 
This should be taken into account when interpreting experi-
ments performed using T reg cells isolated ex vivo.
Protection of T reg cells from NICD by a sdAb to ART2.2
We next asked whether T reg cells could be protected from the 
deleterious effects of NAD+ by acting on the ART2.2–P2X7 
pathway. We recently generated an ART2.2-inhibiting sdAb, 
designated s+16a, from an immunized llama (Koch-Nolte et al., 
2007). One favorable feature of llama sdAbs is a long CDR3 
that can extend into and block the active site of a cognate en-
zyme (De Genst et al., 2006). In vivo, the small (15 kD) sdAbs 
show rapid penetration into tissues (Cortez-Retamozo et al., 
2004). Thus, i.v. injection of sdAb s+16a results in complete 
blockade of ART2.2 on splenic and LN T cells within 10 min 
after injection (Koch-Nolte et al., 2007). We tested whether 
systemic injection of s+16a would protect T reg cells from 
NICD induced by ex vivo preparation. The results demonstrate 
that i.v. injection of s+16a 10 min before euthanizing the mice 
dramatically reduced externalization of PS by WT T reg cells 
(Fig. 3 C). This treatment also efficiently protected T reg   
cells in the highly NICD-susceptible CD38/ background   
(Fig. 3 C). Consistently, T reg cells from both WT and 
CD38/ mice treated with s+16a shed neither CD62L nor 
CD27, another surface molecule sensitive to P2X7 activation 
(Moon et al., 2006), when returned to 37°C (Fig. 3 C).
NAD+ influences the suppressive activity of T reg cells in vitro
It has been observed that T reg cells with a CD62Llo phenotype 
display low suppressive functions (Fu et al., 2004; Ermann   
et al., 2005). Considering that this phenotype may result from 
P2X7 activation, we evaluated the consequences of NAD+ on 
T reg cell function in a classical in vitro suppression assay. 
CD4+CD25+ T reg cells from WT or ART2/ mice were 
added to CD4+CD25 T cells from ART2/ mice and 
Figure 5.  Effect of in vivo administration of NAD+ on the immune 
response against EL4 and EG7 tumors. (A–D) 2 × 105 EL4 (A) or EG7 
(B–D) tumor cells were inoculated s.c. on day 0 into the backs of CD38/ 
or WT mice and tumor growth was followed. Groups of mice (n = 7–8) 
received systemic injections of PBS on day 1 (control), anti-CD25 (PC-61) 
antibody on days 4 and 1, 10 mg (CD38/) or 60 mg (WT) NAD+ on 
day 1, or s+16a-Fc on day 2 followed by NAD injection on day 1. 
(C) WT mice that had been treated with 60 mg NAD+ on day 1 and had 
rejected the primary EG7 tumor received a secondary tumor challenge  
2 mo later with a fivefold higher dose of EG7 tumor cells (106 cells). Control 
group of untreated mice were injected in parallel with the same number 
of EG7 cells. (D) Flow cytometry analyses of lymphocytes from blood sam-
ples taken on days 12–14 after inoculation of EG7 tumor cells. Cells were 
stained for the indicated markers before flow cytometry analyses and 
gating on CD4+ or CD8+ cells. Data are representative of at least three 
independent experiments for each tumor model (with n = 7–8 mice per 
group). Statistical Mann-Whitney U tests were used and showed signifi-
cant differences between tumor volumes in all experiments when com-
paring PBS to NAD-treated animals after day 15. Horizontal lines show 
the mean. **, P < 0.01; ***, P < 0.001. Error bars represent SEM.
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mice displayed significantly higher frequencies of CD4+ and 
CD8+ cells expressing the CD44 activation marker, of CD8+ 
cells expressing granzyme B (GzB), and of anti–Ova-specific 
CD8+ cells (Fig. 5 D). Finally, the phenotype of tumor- 
infiltrating lymphocytes (TILs) was analyzed. As the lym-
phoid EL4 and EG7 tumors express CD4, we turned to the 
B16-Ova model to better discriminate TILs from tumor cells. 
CD4+Foxp3+ cells could be detected among TILs at similar 
frequencies to the control group, which is consistent with a 
recovery of the T reg cell compartment 14 d after NAD+  
injection (unpublished data). However, TILs from NAD-
treated  mice  displayed  significantly  higher  frequencies  of 
CD8+GzB+ cells with higher cell surface levels of the activation 
activated with Con A in the presence of increasing NAD+ 
concentrations. Even in the absence of exogenously added 
NAD+, T reg cells from ART2/ mice were more efficient 
at suppressing T cell proliferation than their WT counterparts 
(Fig. 4 A), which is consistent with their resistance to NAD+ 
released during cell preparation (Fig. 3). Addition of exoge-
nous NAD+ further reduced the suppressive effect of WT   
T reg cells in a dose-dependent manner, whereas it had no   
effect on the function of T reg cells from ART2/ mice   
(Fig. 4 A). Consistently, ART2/ T reg cells were more ef-
ficient than WT T reg cells at suppressing T cell proliferation 
over a broad range of T reg/T conv cell ratios in the absence 
of any exogenous NAD+ addition (Fig. 4 B). These results 
may help explain why classical in vitro suppression assays re-
quire much higher T reg/T conv cell ratios than are observed 
in vivo. The weak suppressive capacities of T reg cells assayed 
in vitro may be, in part, a consequence of exposure to NAD+ 
during cell preparation. Indeed, when T reg cells are insensi-
tive to NAD+, a T reg/T conv cell ratio of 1:10 is sufficient to 
suppress the proliferative response by 50%, whereas a number 
of T reg cells that is five times higher is required for obtaining 
the same effect with WT T reg cells.
Manipulating the ART2–P2X7 pathway to modulate  
the antitumor response
The higher sensitivity of T reg cells to NAD+ may offer an 
opportunity to selectively manipulate the T reg cell com-
partment in vivo by acting on the ART2–P2X7 pathway. 
To explore this possibility, we used the EL4 tumor model, in 
which the antitumor response is naturally suppressed by T reg 
cells and in which T reg cell depletion is sufficient to elicit   
an effective immune response and to inhibit tumor growth 
(Onizuka et al., 1999). As expected, T reg cell depletion by 
administration of an anti-CD25 antibody before transfer of 
tumor cells effectively blocked tumor progression. Remark-
ably, a single i.v. injection of 10 mg NAD+ in CD38/ mice 
or of 60 mg NAD+ in WT mice, i.e., doses that effectively 
deplete 75–80% T reg cells (Fig. 1), 1 d before transfer of EL4 
cells led to efficient control of tumor growth (Fig. 5 A). It is 
of note that the EL4 cell expresses neither ART2.2 nor CD25 
and is insensitive to NAD+ (Fig. S1). Remarkably, the anti-
tumor effect of NAD+ was fully reverted when mice were 
pretreated with an Fc fusion protein of the ART2.2-blocking 
s+16a sdAb, which is consistent with the notion that T reg 
cells are protected from NICD by this ART2.2-blocking Ab 
(Fig. 5 A). Similar effects of NAD+ on tumor growth were 
observed  with  other  lymphoid  and  nonlymphoid  tumors,   
i.e., the EG7 lymphoma (Fig. 5 B), the MCA fibrosarcoma 
(Fig. S2), and the B16 melanoma (Fig. 6 A).
Mice  were  further  analyzed  for  antitumor  T  cell  re-
sponses. NAD-treated mice that had rejected EG7 tumor 
were completely resistant to a secondary tumor challenge   
2 mo later (Fig. 5 C), suggesting that a specific and efficient 
memory T cell antitumor response had been generated in 
those mice. Analysis of blood samples 12–14 d after pri-
mary  tumor  inoculation  demonstrated  that  NAD-treated 
Figure 6.  Effect of in vivo administration of NAD+ on the immune 
response against B16-Ova tumors. Groups of mice (n = 6) received 
systemic injections of PBS on day 1 (control), anti-CD25 (PC-61) anti-
body on day 4 and 1, or 60 mg NAD+ on day 1, followed by the 
inoculation of 2 × 105 B16-Ova tumor cells on day 0. (A) Tumor growth 
was followed over time. (B–D) Groups of mice (n = 6–7) treated as in A 
were killed at days 12–14 for flow cytometry analysis of TILs. (B) Gating 
strategy of CD4+ and CD8+ TILs. (C and D) Representative FACS profiles (C) 
and quantitative analyses (D) of cell surface CD44, intracellular GzB, and 
the ratios of CD8+/CD4+ TILs. Data are representative of three independent 
experiments. Statistical Mann-Whitney U tests showed significant differ-
ences between tumor volumes in all experiments when comparing PBS- 
to NAD-treated animals after day 12. Horizontal lines show the mean.  
**, P < 0.01; ***, P < 0.001. Error bars represent SEM.JEM VOL. 207, November 22, 2010  2567
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activated for 72 h by 2.5 µg/ml Con A in the presence of 5 × 104 splenocytes 
from syngeneic CD3/ mice and pulsed with 0.5 µCi/well of [3H]-TdR 
for the last 24 h of culture. Where indicated, NAD+ was also added at the 
beginning of the co-culture.
Tumor models. All of the following tumor cells used were from the B6 
background: EL4, EL4-Ova (EG7), MCA101-Ova (Zeelenberg et al., 2008), 
and B16-Ova. CD38/ or WT mice received, respectively, 10 or 60 mg 
NAD+ i.v. at day 1. Control groups were treated in parallel with PBS,   
5 µg ART2-blocking s+16a-Fc llama sdAb at day 2, and 250 µg -CD25 
mAb PC-61 at days 4 and 1. All mice were then injected subcutaneously 
on day 0 with 2 × 105 tumor cells into their shaved backs and tumor sizes 
were measured with a digital caliper three times a week. Tumor volume was 
calculated as length × width × [(length + width)/2]. Analysis of TILs was 
performed at days 12–14 by digestion of sliced tumor tissue with collagenase/
dispase/DNase solution for 30 min at 37°C followed by filtration and cen-
trifugation on a 40–70% Percoll density gradient.
Statistical analysis. All data are shown as mean values and error bars repre-
sent SEM. For statistical comparisons, the Mann-Whitney U test was used. 
Differences  were  considered  to  be  statistically  significant  when  p-values 
were <0.05. All calculations were performed using Prism software (Graph-
Pad Software, Inc.).
Online supplemental material. Fig. S1 shows that EL4, EG7, and MCA-
Ova tumor cells are insensitive to NAD+-induced cell death in vitro. Fig. S2 
shows the effect of in vivo administration of NAD+ on MCA-Ova tumor 
growth. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20091154/DC1.
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